Regulatory Aspects, Types and Bioapplications of Metallic Nanoparticles: A Review.

BACKGROUND: Nanotechnology is rapidly advancing in almost every area, such as the pharmaceutical industry, food industry, nano fabrics, electronics, wastewater treatment, and agriculture. INTRODUCTION: Metallic nanoparticles are commonly used in various fields but are especially important in the pharmaceutical industry. Metallic nanoparticles have a size range of 10 nm to 100 nm. METHODS: Two techniques are used to synthesize metallic nanoparticles, the top-down approach and the bottom-up approach. These techniques can be synthesized using three different methods: physical, chemical, and biological. Chemical methods include coprecipitation, reduction, sonochemical, solvothermal, and others, while physical methods include discharge, milling, and ion implantation. Biological methods include plants and their extracts, agricultural wastes, microorganisms, and seaweeds. Scanning electron microscopy, transmission electron microscopy, dynamic light scanning, and other techniques are used to characterize them. RESULTS: All metallic nanoparticles are biocompatible and have special optical, electrical, magnetic, and chemical properties. They are used in various industries, including the pharmaceutical industry as an anticancer agent, antibacterial, antifungal, antioxidant, antidiabetic, and biosensors. Gold, silver, iron oxide, zinc oxide, platinum, copper oxide, and palladium nanoparticles are the most common metal nanoparticles used in the pharmaceutical industry. Monometallic and multimetallic nanoparticles are broadly classified under this. CONCLUSION: This article focuses on the major metallic nanoparticle groups, including synthesis, applications, case studies, toxicity, regulatory aspects and innovative approaches to metallic nanomaterials.

Magnetic-core-based silibinin nanopolymeric carriers for the treatment of renal cell cancer.

AIMS: Silibinin offers potential anticancer effect with less aqueous solubility and high permeability. The present study aimed to develop biocompatible magnetic-core-based nanopolymeric carriers of poly (D, l-lactide-co-glycolic) acid (PLGA) encapsulated silibinin for the sustained release action on renal cancerous cell. MAIN METHODS: The synthesized iron oxide nanoparticles were prepared by precipitation method via encapsulation of silibinin in PLGA network using double emulsion method. The nanoparticle formulations were characterized for morphological, physicochemical properties (HRTEM, FTIR, Raman Spectroscopy and VSM), in vitro drug release and cytotoxicity study on kidney cancer cells (A-498). The safety of magnetic-core-based silibinin nanopolymeric carriers was conducted by i.v. administration at a dose of 50 mg/kg in mice. KEY FINDINGS: The mean particle size, zeta potential and % encapsulation efficiency of magnetic-core-based silibinin nanopolymeric carriers were found to be 285.9 ± 0.28 nm, -14.71 ± 0.15 mV and 84.76 ± 1.29%, respectively. The saturation magnetization of magnetic core and optimized nanoparticles were reported as 36.35 emu/g and 12.78 emu/g, respectively. HRTEM analyses revealed the spherical shapes of the particles with uniform size distribution. The in vitro release profile of silibinin from the nanoparticles exhibited a sustained delivery for 15 days and displayed better cytotoxicity against human kidney cancer cells (A-498) than silibinin. In vivo study showed the safety of magnetic-core-based silibinin nanopolymeric carriers in mice. SIGNIFICANCE: The magnetic-core-based silibinin nanopolymeric carriers will act as a potential carrier for targeted transportation of actives in cancer therapy.

Non-invasive Biodiversified Sensors: A Modernized Screening Technology for Cancer.

BACKGROUND: Biological sensors revolutionize the method of diagnoses of diseases from early to final stages using the biomarkers present in the body. Biosensors are advantageous due to the involvement of minimal sample collection with improved specificity and sensitivity for the detection of biomarkers. METHODS: Conventional biopsies restrict problems like patient non-compliance, cross-infection and high cost and to overcome these issues biological samples like saliva, sweat, urine, tears and sputum progress into clinical and diagnostic research for the development of non-invasive biosensors. This article covers various non-invasive measurements of biological samples, optical-based, mass-based, wearable and smartphone-based biosensors for the detection of cancer. RESULTS: The demand for non-invasive, rapid and economic analysis techniques escalated due to the modernization of the introduction of self-diagnostics and miniature forms of devices. Biosensors have high sensitivity and specificity for whole cells, microorganisms, enzymes, antibodies, and genetic materials. CONCLUSION: Biosensors provide a reliable early diagnosis of cancer, which results in faster therapeutic outcomes with in-depth fundamental understanding of the disease progression.

Nanotherapeutic silibinin: An insight of phytomedicine in healthcare reformation.

Most of the herbal origin drugs possess water insoluble active constituents which lower the bioavailability and increase systemic clearance after administration of repeated or higher dose of drug. Silymarin is extracted from the seeds and fruits of milk thistle plant Silybum marianum which consists of main biologically active component as silibinin. However, the clinical applications of silibinin show some limitations due to low aqueous solubility, poor penetration into the epithelial cells of intestine, high metabolism and rapid systemic elimination. But nanotechnology-based drug delivery system explores great potential for phytochemicals to enhance the aqueous solubility and bioavailability of BCS class II and IV drugs, improve stability and modify the pharmacological activity. This review focuses on the therapeutic properties of silibinin and discusses the benefits, challenges and applications of silibinin nanoformulations. Such nanotherapeutic system as a regular medicine will be an attractive approach to reduce the adverse events and toxicities of current therapies.